ICL

JBT Corporation Announces the Execution of a Definitive Transaction Agreement with Marel hf., Representing a Significant Milestone Towards the Anticipated Launch of a Voluntary Takeover Offer for All Marel Shares

Retrieved on: 
Friday, April 5, 2024
Machine Tools, Metalworking & Metallurgy, Food Tech, Retail, Technology, Manufacturing, Other Technology, Food, Beverage, FSA, Logic, ICL, Icelandic, LEX, Central bank, Goldman Sachs, Form, Nasdaq Iceland, Prospectus, JBT, JBT Corporation, Wells Fargo, Kirkland & Ellis, Security (finance)

(ICL: Marel) have executed a definitive transaction agreement related to JBT’s previously announced intention to make a voluntary takeover offer for all of the issued and outstanding shares of Marel.

Key Points: 
  • (ICL: Marel) have executed a definitive transaction agreement related to JBT’s previously announced intention to make a voluntary takeover offer for all of the issued and outstanding shares of Marel.
  • The transaction agreement includes the terms of the offer and other important governance, social, and operating items relating to the proposed business combination of JBT and Marel.
  • Pending final approval by the FSA, JBT currently expects to launch the offer in May 2024.
  • The transaction is expected to close by the end of 2024, subject to regulatory clearance and applicable shareholder approvals.

STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024

Retrieved on: 
Thursday, April 4, 2024
Optical, Health, Surgery, Medical Devices, ICL, U.S. FDA, Growth, Presbyopia, Near-sightedness, Sale, EVO, Bank statement, Investment, FDA, Astigmatism

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced preliminary net sales for the first quarter ended March 29, 2024, are expected to be in excess of $77 million with U.S. ICL sales expected to be $5 million for the quarter.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced preliminary net sales for the first quarter ended March 29, 2024, are expected to be in excess of $77 million with U.S. ICL sales expected to be $5 million for the quarter.
  • “STAAR is off to a solid start in 2024 as illustrated by our preliminary first quarter results including a record quarter in the U.S.,” said Tom Frinzi, President and CEO of STAAR Surgical.
  • ICL sales were up approximately 20% sequentially to $5 million in the first quarter, which reflects early signs of our increased market focus.
  • The Company expects to report complete first quarter financial results and discuss its fiscal 2024 outlook during its quarterly earnings call on or about May 8, 2024.

STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses

Retrieved on: 
Monday, March 18, 2024
Optical, Health, Surgery, Medical Devices, ICL, Presbyopia, Patient, Iris, American Academy, EVO, Eye, Surgeon, Multimedia, Astigmatism

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that more than three million ICLs have been sold globally.1

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that more than three million ICLs have been sold globally.1
    This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240318771746/en/
    “We extend our sincere gratitude to the surgeons and clinicians with whom we partner and to their patients who have chosen our ICLs for their vision correction as we celebrate our three million lens milestone,” said Tom Frinzi, President and CEO of STAAR Surgical.
  • “EVO ICL is the next logical step in refractive innovation with clear differentiators in patient outcomes and satisfaction.
  • Myopia (nearsightedness) is the most common refractive visual error and is a global epidemic that is expected to impact over half the world’s population by 2050.2
    1 EVO ICL accounts for approximately 2.5 million of the 3 million total ICLs sold.

STAAR Surgical Adds Arthur Butcher and Wei Jiang to Board of Directors

Retrieved on: 
Tuesday, March 12, 2024
Biotechnology, Pharmaceutical, Optical, General Health, Health, Medical Devices, Clinical Trials, Other Health, Eli Lilly, ICL, Boston Scientific, Growth, AstraZeneca, Presbyopia, Eli Lilly and Company, University, Near-sightedness, Art, Columbia University, Indiana State University, EVO, STAAR, Senior, MBA, Bayer, Campbell University, Nursing credentials and certifications, Marketing, CFA, Waters Corporation, Guidant, Retirement, Arthur Butcher, Economics, Astigmatism, Management

“Art Butcher and Wei Jiang are seasoned executives with broad leadership experience built over decades at two of the most highly regarded global companies in the healthcare industry,” said Aimee Weisner, Chair of the Nominating and Governance Committee of STAAR Surgical’s Board of Directors.

Key Points: 
  • “Art Butcher and Wei Jiang are seasoned executives with broad leadership experience built over decades at two of the most highly regarded global companies in the healthcare industry,” said Aimee Weisner, Chair of the Nominating and Governance Committee of STAAR Surgical’s Board of Directors.
  • "Art and Wei also have particular expertise in APAC, the largest market in the world for refractive vision correction.
  • He currently serves as a member of the Board of Directors of Waters Corporation, listed publicly on the New York Stock Exchange.
  • We wish her the best in her future endeavors.”
    With the appointment of Messrs. Butcher and Jiang to the Board, the STAAR Surgical Board is now comprised of eight directors, seven of whom are independent non-employee directors.

Honda North Receives The American Honda President's Award

Retrieved on: 
Friday, March 29, 2024
Trust, ICL, Criterion, Automotive industry

DANVERS, Mass., March 29, 2024 /PRNewswire/ -- Honda North, a proud member and flag ship of the ICL family of dealerships, has once again secured the prestigious President's Award for 2023 from American Honda Motor Co., Inc. This esteemed recognition, bestowed upon top-ranking Honda dealerships nationwide, marks the 16th time Honda North has clinched the title of Top Honda Dealership over a 24 year span!

Key Points: 
  • DANVERS, Mass., March 29, 2024 /PRNewswire/ -- Honda North, a proud member and flag ship of the ICL family of dealerships, has once again secured the prestigious President's Award for 2023 from American Honda Motor Co., Inc.
  • This esteemed recognition, bestowed upon top-ranking Honda dealerships nationwide, marks the 16th time Honda North has clinched the title of Top Honda Dealership over a 24 year span!
  • "We are deeply honored to receive the prestigious Honda Presidents Award", says General Manager, Bryan Laskin.
  • Honda North's 16th win of the President's Award places it among an elite group of Honda dealerships.

Organic Fertilizers Market worth $13.6 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, March 21, 2024
Dry, Nutrient, Transport, Nature, Micronutrient, USD, Phosphorus, Fertilizer, Powder, Potassium, Ground substance, NPK, Risk, Phosphate, Function, Seemabaddha, Water quality, Cereal, Region, Seaweed, Vegetable, Flower, Research, SPIC, Scotts Miracle-Gro Company, Soil, Health, ICL, Farmer, Growth, Nitrogen, Pesticide, Biodiversity

In contrast, organic fertilizers sourced from natural origins offer a more sustainable alternative, reducing chemical runoff and environmental damage.

Key Points: 
  • In contrast, organic fertilizers sourced from natural origins offer a more sustainable alternative, reducing chemical runoff and environmental damage.
  • Total organic sales, inclusive of non-food organic products, reached a record-breaking USD 67.6 billion, highlighting the growing momentum toward environmentally friendly and health-conscious consumption habits.
  • Plant-based organic fertilizers, sourced from materials such as compost, crop residues, seaweed, and green manure crops, are anticipated to experience the highest CAGR during the forecast period in the organic fertilizers market.
  • This trend is expected to persist, positioning North America as a significant contributor to the global organic fertilizers market's expansion.

Organic Fertilizers Market worth $13.6 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, March 21, 2024
Dry, Nutrient, Transport, Nature, Micronutrient, USD, Phosphorus, Fertilizer, Powder, Potassium, Ground substance, NPK, Risk, Phosphate, Function, Seemabaddha, Water quality, Cereal, Region, Seaweed, Vegetable, Flower, Research, SPIC, Scotts Miracle-Gro Company, Soil, Health, ICL, Farmer, Growth, Nitrogen, Pesticide, Biodiversity

In contrast, organic fertilizers sourced from natural origins offer a more sustainable alternative, reducing chemical runoff and environmental damage.

Key Points: 
  • In contrast, organic fertilizers sourced from natural origins offer a more sustainable alternative, reducing chemical runoff and environmental damage.
  • Total organic sales, inclusive of non-food organic products, reached a record-breaking USD 67.6 billion, highlighting the growing momentum toward environmentally friendly and health-conscious consumption habits.
  • Plant-based organic fertilizers, sourced from materials such as compost, crop residues, seaweed, and green manure crops, are anticipated to experience the highest CAGR during the forecast period in the organic fertilizers market.
  • This trend is expected to persist, positioning North America as a significant contributor to the global organic fertilizers market's expansion.

Beckley Waves Celebrates a Year of Milestones, Including $3.3 Million in New Funding, 200 Retreat Participants, the Inaugural Cohort of Therapist Training, and the Acquisition of Ketamine Therapy Provider Nue Life

Retrieved on: 
Tuesday, March 5, 2024
Psilocybin, Mental health, Woman, ICL, Research, Beckley Foundation, Suicide, Spirituality, Curriculum, Entrepreneurship, MDMA, BIPOC, Ketamine, Veteran, PAT, Imperial College London, Partnership

Through its portfolio of operating companies, Beckley Waves has also expanded programs for practitioner training and psilocybin retreats, accelerating the company’s growth.

Key Points: 
  • Through its portfolio of operating companies, Beckley Waves has also expanded programs for practitioner training and psilocybin retreats, accelerating the company’s growth.
  • In September, the company also acquired at-home ketamine therapy provider Nue Life and will continue Nue Life’s work to provide safe and scalable access to ketamine-assisted therapy in underserved areas across multiple US states.
  • In 2024, Beckley Retreats will offer dedicated retreats in Jamaica and the Netherlands that will be exclusively for women, veterans, and the BIPOC community.
  • "With our ongoing momentum, we will keep the flywheel spinning and continue to allow the Beckley Waves Ecosystem to play a catalytic role in our shared path to widespread access."

STAAR Surgical Reports Fourth Quarter and Fiscal Year 2023 Results

Retrieved on: 
Monday, February 26, 2024
Optical, Health, Surgery, Medical Devices, Y/Y, Astigmatism, EVO, ICL, Research, Investment, Patient satisfaction, Marketing, Presbyopia, Growth, Table, Sale, Access, STAAR, ASCRS, Adjustment, Earnings, Advertising, GAAP, Near-sightedness, Depreciation, Pharmaceutical industry

Gross profit margin for the fourth quarter of 2023 was 79.6% of total net sales compared to the prior year quarter of 77.7% of total net sales.

Key Points: 
  • Gross profit margin for the fourth quarter of 2023 was 79.6% of total net sales compared to the prior year quarter of 77.7% of total net sales.
  • Product mix favorably impacted gross margin in the fourth quarter of 2023 as compared to the prior year quarter.
  • Operating expenses for the fourth quarter of 2023 were $50.3 million compared to the prior year quarter of $48.8 million.
  • Operating income for the fourth quarter of 2023 was $10.4 million or 13.7% of net sales as compared to $1.0 million or 1.5% of net sales for the fourth quarter of 2022.

Tellurian Reports 2023 Financial Results and Driftwood LNG Progress

Retrieved on: 
Friday, February 23, 2024
Energy, Other Energy, Oil, Gas, Tellurian Inc, ICL, Driftwood, Plant, Sale, Federal Energy Regulatory Commission, Inc., Bank statement, FERC

Tellurian Inc. (Tellurian or the Company) (NYSE American: TELL) reported its full year 2023 financial results today.

Key Points: 
  • Tellurian Inc. (Tellurian or the Company) (NYSE American: TELL) reported its full year 2023 financial results today.
  • During 2023, Tellurian took significant steps to advance the Driftwood LNG project, having driven over 14,000 piles at site and making progress on concrete foundations for critical equipment thus de-risking site construction.
  • Subsequent to year end, Tellurian amended its senior secured notes and senior convertible notes to provide financial flexibility.
  • As disclosed in our financial statements, we have made significant progress in executing our plans to alleviate substantial doubt.”